L

Lumos Diagnostics Holdings Ltd
ASX:LDX

Watchlist Manager
Lumos Diagnostics Holdings Ltd
ASX:LDX
Watchlist
Price: 0.038 AUD 2.7% Market Closed
Market Cap: 28.4m AUD
Have any thoughts about
Lumos Diagnostics Holdings Ltd?
Write Note

Lumos Diagnostics Holdings Ltd
Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Lumos Diagnostics Holdings Ltd
Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
L
Lumos Diagnostics Holdings Ltd
ASX:LDX
Common Stock
$98.2m
CAGR 3-Years
5%
CAGR 5-Years
51%
CAGR 10-Years
N/A
Nanosonics Ltd
ASX:NAN
Common Stock
AU$114.5m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
4%
Polynovo Ltd
ASX:PNV
Common Stock
AU$191.6m
CAGR 3-Years
11%
CAGR 5-Years
7%
CAGR 10-Years
7%
SDI Ltd
ASX:SDI
Common Stock
AU$12.9m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
Anteris Technologies Ltd
ASX:AVR
Common Stock
AU$283m
CAGR 3-Years
27%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Ansell Ltd
ASX:ANN
Common Stock
$1B
CAGR 3-Years
10%
CAGR 5-Years
3%
CAGR 10-Years
-2%
No Stocks Found

Lumos Diagnostics Holdings Ltd
Glance View

Market Cap
28.4m AUD
Industry
Health Care

Lumos Diagnostics Holdings Ltd. engages in the development and manufacture of point-of-care (POC) diagnostics solutions to help healthcare professionals more accurately diagnose and manage medical conditions. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2021-07-05. The firm's solutions help healthcare professionals to accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and digital reader platforms. The firm's portfolio of product, technology and service offerings include Point-of-care diagnostic products, Point-of-care readers, Commercial services and Manufacturing services. The firm's products include FebriDx and CoviDx. FebriDx is an all-in-one point-of-care test device that can differentiate a viral from bacterial acute respiratory infection. CoviDx is a rapid immunoassay for the detection of the nucleocapsid protein in nasal swabs (NS), oropharyngeal swabs (OP), and nasopharyngeal swabs (NP) from patients suspected of a Coronavirus-19 (COVID-19) infection.

LDX Intrinsic Value
0.169 AUD
Undervaluation 78%
Intrinsic Value
Price
L

See Also

What is Lumos Diagnostics Holdings Ltd's Common Stock?
Common Stock
98.2m USD

Based on the financial report for Jun 30, 2024, Lumos Diagnostics Holdings Ltd's Common Stock amounts to 98.2m USD.

What is Lumos Diagnostics Holdings Ltd's Common Stock growth rate?
Common Stock CAGR 5Y
51%

Over the last year, the Common Stock growth was 6%. The average annual Common Stock growth rates for Lumos Diagnostics Holdings Ltd have been 5% over the past three years , 51% over the past five years .

Back to Top